Novartis stock reaches EUR 143.81 after outlook upgrade
Published on 10/29/2026 at 17:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSStronger core performance, mixed pipeline signals
- Third-quarter sales increased 4 percent, while core operating income advanced 11 percent in US dollars.
- Novartis maintained its low-single-digit sales-growth outlook for 2026.
- A large del-desiran impairment weighed on reported earnings despite stronger adjusted profitability.
- Analyst target revisions remain divided ahead of the November management event.
Novartis stock reached EUR 143.81 at Lang & Schwarz on October 29, 2026, at 4:37 p.m. Berlin time. That was 2.95 percent above the EUR 139.69 quote recorded in the latest relevant report on October 27. The comparison is separate from a Xetra daily close.
Core earnings support the upgrade
The company reported its third-quarter and nine-month results on October 27, 2026. According to RTTNews, third-quarter net sales rose 4 percent to USD 14.522 billion, while core operating income increased 11 percent to USD 6.036 billion. Novartis raised its full-year core operating income outlook from a low-single-digit decline to results broadly in line with the prior year or low-single-digit growth. The full-year sales outlook remained low-single-digit growth.
The adjusted figures came with a weaker reported result. Operating income fell 59 percent and net income declined 70 percent, mainly because of higher research and development costs and a USD 1.9 billion partial impairment related to del-desiran. MarketBeat reported that core earnings per share rose to USD 2.46 and that priority brands, including Kisqali, Kesimpta, Scemblix and Leqvio, supported the quarter.
Analyst views remain cautious
The latest company-specific market analysis shows a split response among analysts. JPMorgan raised its target to CHF 145 and retained an Overweight view, while Bernstein cut its target to CHF 127.08 and UBS raised its target to CHF 130 but kept a Neutral rating. These are separate Swiss-franc targets and should not be confused with the euro quotation.
For investors, the central issue is the contrast between operating momentum and pipeline execution risk. The del-desiran setback and the failed pelacarsen study weigh on reported earnings and development prospects, while newer medicines and productivity measures are supporting the core outlook.
Novartis stock is covered in the real-time quote of Novartis stock.
Market conditions in Switzerland can be followed through the SMI market overview.
Further company-specific developments are available in more news and analyses on Novartis stock.
Novartis AG stock facts
- Company: Novartis AG
- ISIN: CH0012005267
- Primary exchange: SIX Swiss Exchange
- Sector: Healthcare
- Lang & Schwarz price: EUR 143.81 on October 29, 2026, at 4:37 p.m. Berlin time
- Change since the October 27 report: 2.95 percent from EUR 139.69
